6/20/2013

The FDA has cleared Beckman Coulter, a unit of Danaher, to market its Access AccuTnI+3 troponin I test. The assay, which will run on the company's Access 2 immunoassay platform, has been shown in a clinical study to deliver precise as well as clinically sensitive and specific measurements to help doctors diagnose myocardial infarction.

Full Story:
RTT News

Related Summaries